Compare Nokia Corp (NOK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Recursion Pharmaceuticals Inc — how do they compare? Nokia Corp trades at $10.21 (market cap $53.00B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Nokia Corp is far larger — about 29.3× Recursion Pharmaceuticals Inc's market cap, and Nokia Corp pays a 1.73% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NOK | RXRX | |
|---|---|---|
Market Cap | $53.00B | $1.81B |
Sector | Technology | Health |
52-Week High | $16.83 | $6.79 |
52-Week Low | $4.13 | $2.84 |
Enterprise Value | $50.95B | $1.33B |
Dividend Yield | 1.73% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
